Should I buy Medtronic stock in 2025?

Why trust HelloSafe?

At HelloSafe, our experts have been monitoring Medtronic’s performance for over three years. Each month, hundreds of thousands of users in the United States rely on us to interpret market trends and pinpoint the best investment opportunities. Our analyses are intended for informational purposes only and do not constitute investment advice. In line with our ethical charter, we have never been, and will never be, compensated by Medtronic.

What is Medtronic?

How much is Medtronic stock?

The price of Medtronic stock is rising this week. As of today, MDT trades at $83.56, up 1.4% in the past 24 hours and gaining 2.2% over the week. The company’s market capitalization stands at $107.17 billion, with an average trading volume of 5.3 million shares (3-month average). Medtronic’s P/E ratio is 25.48, offering a 3.35% dividend yield and a stock beta of 0.81. With moderate volatility and steady dividend income, Medtronic remains an appealing option for investors focused on both growth and stability.

Our full analysis on Medtronic stock

Having undertaken a rigorous review of Medtronic’s latest financial results, alongside a close analysis of the stock’s trajectory over the past three years, our proprietary composite of financial, technical, and competitive market analytics presents a nuanced portrait of this global medtech leader. By leveraging a multi-source algorithmic approach—blending quantitative market indicators with strategic peer benchmarking—we aim to uncover the precise circumstances under which Medtronic might recapture investor attention as the healthcare technology sector pivots into its next growth phase. So, why might Medtronic stock once again become a strategic entry point into the medtech space in 2025?

Recent Performance and Market Context

Over the past twelve months, Medtronic (NYSE: MDT) has navigated a dynamic period marked by shifting investor sentiment in the healthcare sector. After touching a multi-year low at $75.96 during late 2024, the stock has rebounded to $83.56 as of early May 2025, reflecting renewed institutional confidence and ongoing sector rotation into defensives. Notably, Medtronic’s steady climb has outperformed many pure-play device competitors, especially amid increased macroeconomic volatility and monetary tightening.

• Solid Q3 FY2025 Results: A reported 4.1% organic revenue growth and 6.9% increase in adjusted EPS, both ahead of consensus, have demonstrated the resilience of Medtronic’s diversified portfolio.
• Sector Leadership: Medtronic’s high-single-digit international growth and double-digit expansion in multiple emerging markets underscore its agility and global reach.
• Broader Sector Backdrop: The medical device industry is expected to benefit from robust secular trends—an aging population, heightened chronic disease prevalence, and accelerating innovation cycles—further amplified by healthcare infrastructure investment in both developed and emerging economies.

As the sector regains risk appetite and capital reallocates toward steady dividend payers with credible growth trajectories, Medtronic’s unique positioning becomes increasingly attractive.

Technical Analysis

From a technical standpoint, Medtronic’s chart structure suggests the stock may be crossing a pivotal inflection point. Here’s what our analysis reveals:

• Relative Strength (RSI 14): Currently neutral at 48.15, MDT displays neither significant overbought nor oversold pressure, indicating a base-building phase with minimal risk of an aggressive drawdown.
• MACD (-1.00, 12,26): Still in slightly bearish territory but flattening, often a precursor to momentum shifts that can support early accumulation by informed investors.
• Moving Averages: With the stock price ($83.56) hovering just below its 200-day SMA ($85.61), short-term MAs are trending bullish while mid/long-term trends remain cautious. This configuration often precedes a technical breakout when fundamental catalysts align.
• Support/Resistance Dynamics: Robust support is evident near $82.95—a level repeatedly defended over the past quarter—while initial resistance at $85.80, if breached, could see buying interest escalate.

Overall, technical indicators imply Medtronic is building a firm base, potentially setting the stage for a constructive reversal into the next bullish phase, especially for those seeking to initiate or add positions at relative value levels.

Fundamental Analysis

Medtronic’s recent fiscal results and structural business attributes reinforce a thesis of sustainable long-term growth:

• Revenue Growth and Profitability: Q3 2025 results marked the ninth consecutive quarter of mid-single-digit organic growth, demonstrating impressive consistency in an economically variable environment. Adjusted EPS growth (+6.9% YoY) and gross margin expansion (+50 bps) highlight operational leverage.
• Valuation Attractiveness: With a forward P/E ratio of 14.29—well below its trailing P/E of 25.48—and a price-to-sales ratio of just 3.27, Medtronic appears sensibly valued versus healthcare sector peers, especially when factoring in its robust free-cash-flow profile.
• Portfolio Strength: Medtronic’s balanced business mix (Cardiovascular, Neuroscience, Medical Surgical, Diabetes) not only diversifies risk but also ensures participation in multiple high-growth verticals. The company’s leadership in cardiac devices, neuromodulation, and diabetes solutions is underpinned by world-class R&D and a trusted global brand.
• Dividend Reliability: Its 3.35% yield, paired with a consistent record of dividend growth, appeals to both income-focused and growth-oriented shareholders.

Collectively, these fundamentals validate the view that Medtronic’s shares remain backed by solid intrinsic value and an attractive risk/reward profile.

Volume and Liquidity

Medtronic continues to exhibit liquidity characteristics emblematic of a mega-cap anchor:

• Sustained Trading Volume: Average daily turnover remains robust, reflecting persistent institutional interest and confidence in the stock’s marketability.
• Float/Valuation Dynamics: With a float matched to substantial market cap, the stock benefits from both price stability and the kind of supply/demand imbalances that foster technical rallies, especially near fundamental inflection points.

In this context, elevated liquidity provides shareholders with flexibility to scale positions with minimal impact cost, while ensuring responsiveness to positive news flow.

Catalysts and Positive Outlook

Several key growth catalysts strongly underpin Medtronic’s bullish outlook over multiple horizons:

• Pulse Field Ablation (PFA): The surge in adoption of Affera and PulseSelect platforms is driving Medtronic’s Cardiac Ablation franchise toward a $2 billion annualized run-rate. With PFA’s paradigm-shifting efficacy, market penetration is poised to accelerate, especially as global rollouts mature.
• Renal Denervation (RDN): With pivotal CMS reimbursement activity and Medicare national coverage expected, Medtronic’s Simplicity RDN procedure stands to unlock a multi-billion dollar hypertension market, reshaping standard-of-care and fueling revenue inflection.
• Diabetes Franchise Momentum: The MiniMed 780G system continues on a double-digit growth trajectory, while pending FDA approvals for Simplera Sync sensors and potential Type 2 diabetes expansion offer substantial path-dependent optionality.
• Robotic Surgery (Hugo): Approaching FDA submission milestones, the Hugo robotic platform is set to disrupt a global market hungry for surgical automation, introducing high-margin, recurring revenue potential.
• ESG and Innovation: Medtronic’s deep commitment to environmental, social, and governance initiatives further enhances its appeal to sustainability-centric capital, while core R&D efforts advance next-generation digital therapeutics, AI-driven diagnostics, and personalized care platforms.

The convergence of these drivers not only elevates near-term momentum but also underpins a secular growth story extending well into the coming decade.

Investment Strategies

Medtronic’s stock profile fits a range of sophisticated investment approaches, each uniquely positioned to capitalize on the current opportunity set:

• Short-Term Catalysts: Recent support at $82.95 and anticipation of upcoming product launches (notably in diabetes and robotics) allow for tactical entry opportunities, particularly for investors seeking to front-run near-term earnings or regulatory events.
• Medium-Term Thesis: Resolution of transitory headwinds—such as distributor-related softness in the Medical Surgical division—combined with progressing innovation cycles, suggest the potential for both earnings and multiple expansion during the next four quarters.
• Long-Term Positioning: For patient, fundamental investors, Medtronic’s balance of income yield, proven growth engine, and emerging market upside offers a compelling recipe for compounding total returns over time.

Each approach is reinforced by technical evidence that the current zone represents a favorable risk-adjusted entry point—either for fresh positions or ongoing accumulation ahead of expected catalysts.

Is It the Right Time to Buy Medtronic?

In aggregate, Medtronic’s combination of consistent financial delivery, accelerating innovation, improving margins, and credible valuation levels makes a compelling case for its place in a forward-looking healthcare portfolio. Today, MDT appears attractively positioned at both a technical and fundamental low, with clear upside catalysts set to emerge throughout the next 12–24 months.

When viewed against the backdrop of resilient sector dynamics, dynamic product innovation, and flexible capital allocation, Medtronic’s risk/reward profile seems to represent an excellent opportunity for investors seeking both growth and defensiveness within the healthcare technology sphere. With a robust stream of catalysts on the horizon and a firm commitment to shareholder value, the stock’s fundamentals justify renewed interest and point toward a potentially rewarding period ahead.

For investors ready to embrace a leader that pairs global healthcare reach with accelerating innovation, Medtronic stands out as a stock that may be on the cusp of entering a new bullish phase—well-worth strong consideration as a core holding for the evolving medtech cycle.

How to buy Medtronic stock in United States?

Buying Medtronic stock online is a straightforward and secure process when you use a regulated broker in the United States. Investors can choose between two main methods: purchasing shares directly (spot buying) for long-term holding, or trading Medtronic via Contracts for Difference (CFDs), which allows speculation on short-term price movements with leverage. Both options are accessible through leading online platforms, typically requiring just a few clicks to get started. To help you make the best choice for your needs, you'll find a comprehensive broker comparison further down this page.

Spot Buying

A cash (spot) purchase involves buying Medtronic (MDT) shares directly through your brokerage account. This method gives you actual ownership of the shares, making you eligible for dividends and voting rights. Typically, U.S. brokers charge a fixed commission per order, which often ranges from $0 to $10, depending on the platform.

Example

For example, if Medtronic is trading at $83.56 per share, a $1,000 investment (including a $5 brokerage fee) allows you to purchase around 11 shares.
✔️ Gain scenario: If the share price rises by 10%, your 11 shares would now be worth about $1,100.
Result: That's a gross gain of $100, a +10% return on your initial investment.

CFD Trading

Trading Medtronic via CFDs (Contracts for Difference) means speculating on the stock's price without owning the actual shares. This method lets you use leverage, amplifying both gains and losses. With CFDs, fees come from the spread (difference between buy and sell price) and overnight financing costs if you hold positions for more than one day.

Example

For instance, with a $1,000 stake and 5x leverage, you can open a CFD position worth $5,000 on Medtronic.
✔️ Gain scenario: If the stock price increases by 8%, your leveraged position returns 8% × 5 = 40%.
Result: You make a $400 gain on your $1,000 investment (excluding fees).

Final Advice

Before investing in Medtronic, it's essential to compare the fees, trading conditions, and services offered by different online brokers. Whether you choose direct share ownership for long-term growth and dividends, or CFD trading for short-term speculation, the best option depends on your investment strategy and risk tolerance. For detailed information on top brokers and their conditions, be sure to check our comparison tool further down on this page.

Application

Rates & Fees

Learn More

#1

30+ million users

#1Recommended by Forbes

eToro

Rates & Fees

4.9

Discover

51% of CFD accounts lose money. You will never lose more than your investment.

#2

CFD and Indices Expert

#2

IG

Rates & Fees

4.9

Discover

74% of CFD accounts lose money. Your capital is at risk.

#3

CFD specialist

#3

Avatrade

Rates & Fees

4.8

On the broker's website

Our 7 tips for buying Medtronic stock

The latest news about Medtronic

Medtronic reported robust Q3 fiscal 2025 results, surpassing analyst expectations on both earnings and revenue. The company delivered worldwide revenue of $8.292 billion, representing a 2.5% increase as reported and 4.1% organic growth, while adjusted EPS grew by 6.9% to $1.39, exceeding consensus by $0.03. Notably, margins expanded year-over-year, with gross margin at 66.6% and operating margin at 26.2%. These results mark Medtronic's ninth consecutive quarter of mid-single-digit revenue growth and demonstrate the company’s resilience and consistency in its core U.S. market, further supporting confidence in future earnings momentum.

The diabetes business delivered its fifth consecutive quarter of double-digit growth, driven by strong U.S. performance and product innovation. Medtronic’s Diabetes Operating Unit achieved 10% growth, fueled by the success of the MiniMed 780G system, which continues to penetrate the U.S. market with high CGM (Continuous Glucose Monitoring) attachment rates. Upcoming launches, such as the Simplera Sync sensor pending FDA approval, point to further momentum, particularly as the company targets expanded labeling for Type 2 diabetes. This signals sustained growth potential in a key segment with significant relevance to the U.S. patient population.

Significant progress was made in Medtronic’s U.S. innovation pipeline, especially in cardiac ablation and robotic surgery systems. Pulse Field Ablation (PFA) products in Cardiac Ablation Solutions saw 22% growth, with products like Affera and PulseSelect spearheading U.S. expansion. Management anticipates this platform to surpass $1 billion in annual revenue and double as adoption grows nationwide. Additionally, the Hugo robotic-assisted surgery system approaches major milestones, including FDA submission for urology indications and the start of GYN oncology trials. These innovation drivers enhance Medtronic’s competitive position in the U.S. medtech landscape.

Medtronic anticipates a major reimbursement catalyst for its renal denervation (RDN) therapy, setting the stage for accelerated U.S. adoption. The Simplicity blood pressure procedure has secured Medicare coding and payment, and the national coverage analysis process initiated by CMS is expected to deliver broad Medicare coverage within eight months. This upcoming policy shift should unlock significant demand for RDN therapy in U.S. hospitals and clinics, representing a substantial growth driver once fully implemented.

The company reaffirmed its full-year 2025 outlook, projecting high-single-digit adjusted EPS growth in the second half and strong free cash flow generation. Medtronic’s management reiterated guidance of 4.75%-5% organic revenue growth and non-GAAP diluted EPS of $5.44 to $5.50 for fiscal 2025, with an expected acceleration in both revenue and earnings into the next quarter. The company continues to emphasize durable growth, leveraging operational efficiencies and strong U.S. presence, underpinned by a consistent dividend yield of 3.35%, which remains attractive for income-focused investors.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.